347 related articles for article (PubMed ID: 25185992)
1. Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Aliment Pharmacol Ther; 2014 Nov; 40(9):1044-55. PubMed ID: 25185992
[TBL] [Abstract][Full Text] [Related]
2. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
Baert F; Glorieus E; Reenaers C; D'Haens G; Peeters H; Franchimont D; Dewit O; Caenepeel P; Louis E; Van Assche G;
J Crohns Colitis; 2013 Mar; 7(2):154-60. PubMed ID: 22537637
[TBL] [Abstract][Full Text] [Related]
4. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.
Billioud V; Sandborn WJ; Peyrin-Biroulet L
Am J Gastroenterol; 2011 Apr; 106(4):674-84. PubMed ID: 21407178
[TBL] [Abstract][Full Text] [Related]
5. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients.
Bultman E; de Haar C; van Liere-Baron A; Verhoog H; West RL; Kuipers EJ; Zelinkova Z; van der Woude CJ
Aliment Pharmacol Ther; 2012 Feb; 35(3):335-41. PubMed ID: 22191671
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab.
Duveau N; Nachury M; Gerard R; Branche J; Maunoury V; Boualit M; Wils P; Desreumaux P; Pariente B
Dig Liver Dis; 2017 Feb; 49(2):163-169. PubMed ID: 27899263
[TBL] [Abstract][Full Text] [Related]
7. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.
Ma C; Beilman CL; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Inflamm Bowel Dis; 2016 Apr; 22(4):870-9. PubMed ID: 26818419
[TBL] [Abstract][Full Text] [Related]
8. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T
Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921
[TBL] [Abstract][Full Text] [Related]
9. Editorial: adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.
Moss AC
Aliment Pharmacol Ther; 2014 Nov; 40(10):1249. PubMed ID: 25303382
[No Abstract] [Full Text] [Related]
10. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients.
Swaminath A; Ullman T; Rosen M; Mayer L; Lichtiger S; Abreu MT
Aliment Pharmacol Ther; 2009 Feb; 29(3):273-8. PubMed ID: 19006540
[TBL] [Abstract][Full Text] [Related]
11. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.
Kiss LS; Szamosi T; Molnar T; Miheller P; Lakatos L; Vincze A; Palatka K; Barta Z; Gasztonyi B; Salamon A; Horvath G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovasz BD; Vegh Z; Golovics PA; Szathmari M; Papp M; Lakatos PL;
Aliment Pharmacol Ther; 2011 Oct; 34(8):911-22. PubMed ID: 21883326
[TBL] [Abstract][Full Text] [Related]
12. Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease.
Brandse JF; Peters CP; Gecse KB; Eshuis EJ; Jansen JM; Tuynman HA; Löwenberg M; Ponsioen CY; van den Brink GR; DʼHaens GR;
Inflamm Bowel Dis; 2014 Feb; 20(2):251-8. PubMed ID: 24378599
[TBL] [Abstract][Full Text] [Related]
13. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
Cohen RD; Lewis JR; Turner H; Harrell LE; Hanauer SB; Rubin DT
Inflamm Bowel Dis; 2012 Jan; 18(1):10-6. PubMed ID: 21456032
[TBL] [Abstract][Full Text] [Related]
14. [Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
Kiss LS; Szamosi T; Molnár T; Miheller P; Lakatos L; Vincze A; Palatka K; Bartha Z; Gasztonyi B; Salamon A; Horváth G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovász BD; Végh Z; Golovics PA; Szathmári M; Papp M; Lakatos PL
Orv Hetil; 2011 Sep; 152(36):1433-42. PubMed ID: 21865144
[TBL] [Abstract][Full Text] [Related]
15. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
[TBL] [Abstract][Full Text] [Related]
16. Temporary adalimumab dose escalation is effective in Crohn's disease patients with secondary non-response.
Sutharshan K; Gearry RB
J Crohns Colitis; 2013 Aug; 7(7):e277-8. PubMed ID: 23434316
[No Abstract] [Full Text] [Related]
17. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab for Crohn's disease: long-term sustained benefit in a population-based cohort of 438 patients.
Peters CP; Eshuis EJ; Toxopeüs FM; Hellemons ME; Jansen JM; D'Haens GR; Fockens P; Stokkers PC; Tuynman HA; van Bodegraven AA; Ponsioen CY;
J Crohns Colitis; 2014 Aug; 8(8):866-75. PubMed ID: 24491515
[TBL] [Abstract][Full Text] [Related]
19. Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study.
Pouillon L; Lamoureux A; Pineton de Chambrun G; Vuitton L; Pariente B; Zallot C; Dufour G; Fumery M; Baumann C; Amiot A; Nancey S; Rousseau H; Peyrin-Biroulet L
Dig Liver Dis; 2019 Feb; 51(2):236-241. PubMed ID: 30502230
[TBL] [Abstract][Full Text] [Related]
20. Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.
Van Steenbergen S; Bian S; Vermeire S; Van Assche G; Gils A; Ferrante M
Aliment Pharmacol Ther; 2017 Apr; 45(7):923-932. PubMed ID: 28164321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
